Epidermal growth factor receptor (EGFR) amplification and telomerase reverse transcriptase promoter (TERTp) mutation status of isocitrate dehydrogenase-wildtype (IDHwt) lower-grade gliomas (LGGs; grade II/III) are crucial for identifying IDHwt LGG with an aggressive clinical course. The purpose of this study was to assess whether parameters from diffusion tensor imaging, dynamic susceptibility contrast (DSC), and diffusion tensor imaging, dynamic contrast-enhanced imaging can predict the EGFR amplification and TERTp mutation status of IDHwt LGGs.
A total of 49 patients with IDHwt LGGs with either known EGFR amplification (39 non-amplified, 10 amplified) or TERTp mutation (19 wildtype, 21 mutant) statuses underwent MRI. The mean ADC, fractional anisotropy (FA), normalized cerebral blood volume (nCBV), normalized cerebral blood flow (nCBF), volume transfer constant (Ktrans), rate transfer coefficient (Kep), extravascular extracellular volume fraction (Ve), and plasma volume fraction (Vp) values were assessed. Univariate and multivariate logistic regression models were constructed.
EGFR-amplified tumors showed lower mean ADC values than EGFR-non-amplified tumors (p = 0.019). Mean ADC was an independent predictor of EGFR amplification, with an AUC of 0.75. TERTp mutant tumors showed higher mean nCBV (p = 0.020), higher mean nCBF (p = 0.017), and higher mean Vp (p = 0.002) than TERTp wildtype tumors. With multivariate logistic regression, mean Vp was the independent predictor of TERTp mutation status, with an AUC of 0.85.
This exploratory pilot study shows that lower ADC values may be useful for prediction of EGFR amplification, whereas higher Vp values may be useful for prediction of the TERTp mutation status of IDHwt LGGs.
• EGFR amplification and TERTp mutation are key molecular markers that predict an aggressive clinical course of IDHwt LGGs.
• EGFR-amplified tumors showed lower ADC values than EGFR-non-amplified tumors, suggesting higher cellularity.
• TERTp mutant tumors showed a higher plasma volume fraction than TERTp wildtype tumors, suggesting higher vascular proliferation and tumor angiogenesis.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy
Cerebral blood volume
Dynamic susceptibility contrast
Diffusion tensor imaging
Epidermal growth factor receptor
Fluid-attenuated inversion recovery
Field of view
- K ep :
Rate transfer coefficient
- K trans :
Volume transfer constant
Normalized cerebral blood volume
Normalized cerebral blood flow
Telomerase reverse transcriptase promoter
- V e :
Extravascular extracellular volume fraction
Variance inflation factor
- V p :
Plasma volume fraction
World Health Organization
Louis DN, Perry A, Reifenberger G et al (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131:803–820
Brat DJ, Verhaak RG, Aldape KD et al (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498
Eckel-Passow JE, Lachance DH, Molinaro AM et al (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508
Wijnenga MM, Dubbink HJ, French PJ et al (2017) Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Acta Neuropathol 134:957–959
Weller M, Weber RG, Willscher E et al (2015) Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome-and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. Acta Neuropathol 129:679–693
Brat DJ, Aldape K, Colman H et al (2018) cIMPACT-NOW update 3: recommended diagnostic criteria for “diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”. Acta Neuropathol 136:805–810
Bai J, Varghese J, Jain R (2020) Adult glioma WHO classification update, genomics, and imaging: what the radiologists need to know. Top Magn Reson Imaging 29:71–82
Chen J, McKay RM, Parada LF (2012) Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell 149:36–47
Arita H, Narita Y, Fukushima S et al (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126:267–276
Kim DH, Mohapatra G, Bollen A, Waldman FM, Feuerstein BG (1995) Chromosomal abnormalities in glioblastoma multiforme tumors and glioma cell lines detected by comparative genomic hybridization. Int J Cancer 60:812–819
Choi Y, Ahn S, Lee H-J et al (2017) The initial area under the curve derived from dynamic contrast-enhanced MRI improves prognosis prediction in glioblastoma with unmethylated MGMT promoter. AJNR Am J Neuroradiol 38:1528–1535
Ahn SS, Shin N-Y, Chang JH et al (2014) Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging. J Neurosurg 121:367–373
Choi Y, Kim D, Lee S-K et al (2015) The added prognostic value of preoperative dynamic contrast-enhanced MRI histogram analysis in patients with glioblastoma: analysis of overall and progression-free survival. AJNR Am J Neuroradiol 36:2235–2241
Chenevert TL, Brunberg JA, Pipe JG (1990) Anisotropic diffusion in human white matter: demonstration with MR techniques in vivo. Radiology 177:401–405
Hansen JR (1971) Pulsed NMR study of water mobility in muscle and brain tissue. Biochim Biophys Acta 230:482–486
Yan H, Parsons DW, Jin G et al (2009) IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–773
Takano S, Tian W, Matsuda M et al (2011) Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing. Brain Tumor Pathol 28:115–123
Sahm F, Schrimpf D, Jones DT et al (2016) Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. Acta Neuropathol 131:903–910
Na K, Kim H-S, Shim HS, Chang JH, Kang S-G, Kim SH (2019) Targeted next-generation sequencing panel (TruSight Tumor 170) in diffuse glioma: a single institutional experience of 135 cases. J Neurooncol 142:445–454
Tofts PS, Brix G, Buckley DL et al (1999) Estimating kinetic parameters from dynamic contrast-enhanced T1-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magnet Reson Imaging 10:223–232
Weisskoff R, Boxerman J, Sorensen A, Kulke S, Campbell T, Rosen B (1994) Simultaneous blood volume and permeability mapping using a single Gd-based contrast injection. Proceedings of the Society of Magnetic Resonance, Second Annual Meeting, pp 6–12
Boxerman J, Schmainda K, Weisskoff R (2006) Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 27:859–867
Cha J, Kim S, Kim H-J et al (2014) Differentiation of tumor progression from pseudoprogression in patients with posttreatment glioblastoma using multiparametric histogram analysis. AJNR Am J Neuroradiol 35:1309–1317
Maes F, Collignon A, Vandermeulen D, Marchal G, Suetens P (1997) Multimodality image registration by maximization of mutual information. IEEE Trans Med Imaging 16:187–198
Aibaidula A, Chan AK-Y, Shi Z et al (2017) Adult IDH wild-type lower-grade gliomas should be further stratified. Neuro Oncology 19:1327–1337
Park YW, Han K, Ahn SS et al (2018) Prediction of IDH1-mutation and 1p/19q-codeletion status using preoperative MR imaging phenotypes in lower grade gliomas. AJNR Am J Neuroradiol 39:37–42
Park YW, Han K, Ahn SS et al (2018) Whole-tumor histogram and texture analyses of DTI for evaluation of IDH1-mutation and 1p/19q-codeletion status in World Health Organization grade II gliomas. AJNR Am J Neuroradiol 39:693–698
Park CJ, Choi YS, Park YW et al (2020) Diffusion tensor imaging radiomics in lower-grade glioma: improving subtyping of isocitrate dehydrogenase mutation status. Neuroradiology 62(3):319–326
Park YW, Choi YS, Ahn SS, Chang JH, Kim SH, Lee S-K (2019) Radiomics MRI phenotyping with machine learning to predict the grade of lower-grade gliomas: a study focused on nonenhancing tumors. Korean J Radiol 20:1381–1389
Li Y, Liu X, Xu K et al (2018) MRI features can predict EGFR expression in lower grade gliomas: a voxel-based radiomic analysis. Eur Radiol 28:356–362
Young RJ, Gupta A, Shah A et al (2013) Potential role of preoperative conventional MRI including diffusion measurements in assessing epidermal growth factor receptor gene amplification status in patients with glioblastoma. AJNR Am J Neuroradiol 34:2271–2277
Lal A, Glazer CA, Martinson HM et al (2002) Mutant epidermal growth factor receptor up-regulates molecular effectors of tumor invasion. Cancer Res 62:3335–3339
Gupta A, Young R, Shah A et al (2015) Pretreatment dynamic susceptibility contrast MRI perfusion in glioblastoma: prediction of EGFR gene amplification. Clin Neuroradiol 25:143–150
Tykocinski ES, Grant RA, Kapoor GS et al (2012) Use of magnetic perfusion-weighted imaging to determine epidermal growth factor receptor variant III expression in glioblastoma. Neuro Oncology 14:613–623
Kickingereder P, Bonekamp D, Nowosielski M et al (2016) Radiogenomics of glioblastoma: machine learning–based classification of molecular characteristics by using multiparametric and multiregional MR imaging features. Radiology 281:907–918
Arevalo-Perez J, Thomas A, Kaley T et al (2015) T1-weighted dynamic contrast-enhanced MRI as a noninvasive biomarker of epidermal growth factor receptor vIII status. AJNR Am J Neuroradiol 36:2256–2261
Keller S, Schmidt M (2017) EGFR and EGFRvIII promote angiogenesis and cell invasion in glioblastoma: combination therapies for an effective treatment. Int J Mol Sci 18:1295
Dunn IF, Heese O, Black PM (2000) Growth factors in glioma angiogenesis: FGFs, PDGF, EGF, and TGFs. J Neurooncol 50:121–137
Labussiere M, Di Stefano A, Gleize V et al (2014) TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer 111:2024
Takahashi M, Miki S, Fukuoka K et al (2017) EXTH-50. Development of investigator initiated clinical trial of TERT-targeting therapy using eribulin mesylate in patients with recurrent glioblastoma. Neuro Oncology 19:vi83
Ersoy TF, Keil VC, Hadizadeh DR et al (2017) New prognostic factor telomerase reverse transcriptase promotor mutation presents without MR imaging biomarkers in primary glioblastoma. Neuroradiology 59:1223–1231
Yamashita K, Hatae R, Hiwatashi A et al (2019) Predicting TERT promoter mutation using MR images in patients with wild-type IDH1 glioblastoma. Diagn Interv Imaging 100(7–8):411–419
Ivanidze J, Lum M, Pisapia D et al (2019) MRI features associated with TERT promoter mutation status in glioblastoma. J Neuroimaging 29:357–363
Low KC, Tergaonkar V (2013) Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci 38:426–434
Pallini R, Pierconti F, Falchetti ML et al (2001) Evidence for telomerase involvement in the angiogenesis of astrocytic tumors: expression of human telomerase reverse transcriptase messenger RNA by vascular endothelial cells. J Neurosurg 94:961–971
Nguyen T, Cron G, Mercier J et al (2015) Preoperative prognostic value of dynamic contrast-enhanced MRI–derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas. AJNR Am J Neuroradiol 36:63–69
Larsson HB, Hansen AE, Berg HK, Rostrup E, Haraldseth O (2008) Dynamic contrast-enhanced quantitative perfusion measurement of the brain using T1-weighted MRI at 3T. J Magn Reson Imaging 27:754–762
Alcaide-Leon P, Pareto D, Martinez-Saez E, Auger C, Bharatha A, Rovira A (2015) Pixel-by-pixel comparison of volume transfer constant and estimates of cerebral blood volume from dynamic contrast-enhanced and dynamic susceptibility contrast-enhanced MR imaging in high-grade gliomas. AJNR Am J Neuroradiol 36:871–876
Stichel D, Ebrahimi A, Reuss D et al (2018) Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Acta Neuropathol 136:793–803
This research received funding from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Science, ICT & Future Planning (2017R1D1A1B03030440), and from the Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2020R1I1A1A0107164811).
The scientific guarantor of this publication is Professor Seung-Koo Lee, MD, PhD, from Yonsei University College of Medicine (firstname.lastname@example.org).
Conflict of interest
The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.
Statistics and biometry
One of the authors has significant statistical expertise (K.H, a biostatistician with 10 years of experience in biostatistics).
Only if the study is on human subjects: The institutional review board waived the requirement to obtain informed patient consent for this retrospective study.
Only if the study is on animals: This study was performed only on human subjects.
Institutional Review Board approval was obtained.
• diagnostic or prognostic study
• performed at one institution
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Park, Y.W., Ahn, S.S., Park, C.J. et al. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Eur Radiol 30, 6475–6484 (2020). https://doi.org/10.1007/s00330-020-07090-3
- Epidermal growth factor receptor
- Magnetic resonance imaging
- Telomerase reverse transcriptase